Innovative payment schemes for medical technologies in Europe in 2021
Syndicated report (135 pages) with the overview and statistics of key innovation funding and coverage with evidence development schemes in eight European countries
Innovative payment schemes are an important part of the reimbursement landscape for medical technologies. Two key types of schemes are unconditional innovation payment (when payment is provided for innovation unconditionally) and coverage with evidence development (when either financing for a study or coverage with the obligation to perform the study is provided to medical technology).
MTRC has developed an in-depth overview of the innovative payment schemes, active in 2021 in eight European countries, including detailed statistics about the activity of the schemes. This report is built on the 2018 report, sponsored by the Med Tech Europe, but it includes a significant revision of several sections, an update of all statistical information, and several completely new sections (G-BA Innovation Fund in Germany, New subsidy for promising care in the Netherlands, Article 51 of the Social Security Law in France, Med Tech Funding Mandate in England).
This report complements the series of MTRC analytical reports in the field of reimbursement for medical technologies, including reports on HTA for medical technologies in 2019 and funding frameworks and decisions for medical technologies.
Key features of the report
8 EU countries
Innovative payment schemes from Austria, Belgium, England, France, Germany, the Netherlands, Spain and Switzerland are included
21 payment schemes
Three unconditional innovation payment, 18 coverage with evidence development (CED) schemes are reviewed
Devices, procedures, IVD tests and digital technologies
Only schemes related to medical technologies and procedures are included. Pharmaceutical schemes are not considered
Overview of payment framework
Objective, description, inclusion criteria, applicant, stakeholders involved, clinical and economic evidence requirements, statistics about the scheme
Key statistics on the scheme
Number and list of published decisions in the recent years or in 2019-2021
Obtain sample pages
Click to the link below to obtain sample pages, including the whole chapter for Restricted Clinical Application mechanism in Belgium
Get sample pages
Specifics of the report
Austria: Provisional procedure codes for new diagnostic or therapeutic methods (NUB);
Belgium: Restricted Clinical Application for invasive medical devices and implants (Application Clinique Limité); Temporary Reimbursement of Software Applications (level 3-);
England: Artificial Intelligence in Health & Care Award England (Phase 4); Innovation competition at the NHS Cancer Programme; Medtech Funding Mandate;
France: Health Economic Research Program (PRME), Innovation Package (forfait innovation); List of biological and anatomocytopathology innovative acts outside the nomenclature (RIHN), Article 51 of the Social Security Law; Provisional Registration of Medical Procedures (Prise en Charge Provisoire); Transitional Coverage of Medical Devices (Prise en Charge Transitoire);
Germany: New diagnostic or therapeutic methods (Neue Untersuchungs- und Behandlungsmethoden, NUB); Government-co-sponsored studies according to the §137e of the German Social Code Book V, G-BA Innovation Fund; Provisional listing of Digital Health Applications (DiGA)
Netherlands: Small-scale experiments for the introduction of innovations (Innovatie voor kleinschalige experimenten), subsidy scheme for promising care;
Switzerland: Provisional reimbursement of medical procedures, IVD tests and medical aids (Leistungen in Evaluation).
Request a quote
Click the button below to request a quote for the report
